Lung cancer immunotherapy combo trial halted early – what we know
NCT ID NCT04832854
First seen Mar 19, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This study tested two immunotherapy drugs (tiragolumab and atezolizumab) given before and after surgery, with or without chemotherapy, for people with early-stage non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors enough to make surgery easier. The trial was terminated early, so only limited safety and effectiveness data are available from the 50 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032-3725, United States
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
Corporacio Sanitaria Parc Tauli
Sabadell, Barcelona, 08208, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Kantonsspital Baden
Baden, 5404, Switzerland
-
Kantonsspital Graubünden Medizin Onkologie
Chur, 7000, Switzerland
-
Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
-
Kantonsspital Winterthur
Winterthur, 8401, Switzerland
-
NYU Cancer Center
New York, New York, 10016, United States
-
Peter Maccallum Cancer Institute
Melbourne, Victoria, 3000, Australia
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
St. Vincent's Hospital
Gyeonggi-do, 16247, South Korea
-
Sunshine Coast University Hospital
Birtinya, Queensland, 4575, Australia
-
University of Southern California
Los Angeles, California, 90033, United States
-
UniversitätsSpital Zürich
Zurich, 8091, Switzerland
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Winthrop Univ Hospital
Mineola, New York, 11501, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tiragolumab and atezolizumab (immunotherapy drugs), with or without platinum-based chemotherapy
What this could lead to
If successful, this approach could improve outcomes for patients with early-stage lung cancer by shrinking tumors before surgery and reducing the chance of cancer coming back afterward.
What could go wrong
The trial was terminated early, so results are limited. Immunotherapies can cause immune-related side effects, and adding chemotherapy increases toxicity. The small size (50 participants) and early phase mean any benefits are uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.